BioCentury | May 20, 2019
Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

...the endpoint required significance at all nine. OTX-TP is an intracanalicular insert that delivers sustained-release travoprost...
...1 Brian Moy, Assistant Editor Entyvio, vedolizumab (MLN0002) inclisiran (aln-pcssc, pcsk9si) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Nuplazid, pimavanserin (ACP-103, pimavanserin tartrate) Sustained-release travoprost...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...atrophy (SMA) type 1 FDA action; EC action June; mid-2019 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...II diabetes Submit MAA and NDA; submit Japanese NDA 1H19 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...women with low fertility Ph III IMPLANT 2 data 1Q18 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost...
BioCentury | Oct 10, 2016
Clinical News

Sustained-release travoprost: Phase III started

...within the canaliculus in about 550 patients. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Sustained-release travoprost...
...OTX-TP ) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Feb 18, 2016
Clinical News

Ocular Therapeutix rises on OTX-TP update

...program. In a previous study, timolol outperformed OTX-TP, a hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Nov 2, 2015
Clinical News

Sustained-release travoprost: Phase IIb data

...and no serious adverse events were reported. Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Sustained-release travoprost...
...OTX-TP ) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
BioCentury | Oct 12, 2015
Clinical News

ENV515: Phase IIa data

...reduction was the same as the 28% reduction achieved by patients who received once-daily Travatan Z travoprost...
...procedure. Patients received 1 of 4 doses of ENV515 in the study eye and once-daily Travatan Z...
...Research Triangle Park, N.C. Product: ENV515 Business: Ophthalmic Molecular target: NA Description: Extended-release formulation of travoprost...
BioCentury | Oct 7, 2015
Clinical News

Envisia's ENV515 matches Travatan Z in glaucoma study

...travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study, and was comparable to Travatan Z travoprost...
...baseline IOP by 28% at day 25 (p<0.001), which was comparable to daily doses of Travatan Z...
...of travoprost, a prostaglandin analog that inhibits neovascularization in the eye. Envisia's extended-release formulation of travoprost...
BioCentury | Dec 15, 2014
Clinical News

Sustained Release Travoprost: Phase IIb started

...double-blind, U.S. Phase IIb trial to compare a single dose of 0.36 mg Sustained Release Travoprost...
...Release Travoprost (OTX-TP) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release travoprost...
Items per page:
1 - 10 of 36